TME PHARM.CONF.IPO EO 1-
Research TME PHARM.CONF.IPO EO 1- (0N6A) on Bullrun: market cap EUR 13.19M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker0N6A
- ExchangeF
- CountryGermany
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 13.19M
- Financial periodFY2025
- RevenueEUR 0
- Net income-EUR 3.29M
- Free cash flow-EUR 3.42M
Valuation Snapshot
latest market cap is EUR 13.19M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 0 | -EUR 3.29M | -EUR 3.42M | n/a | n/a | EUR 2.01M | EUR 2.39M | -EUR 1.58M |
| FY2024 | EUR 0 | -EUR 5.72M | -EUR 4.65M | n/a | n/a | EUR 3.24M | EUR 0 | EUR 1.61M |
| FY2023 | EUR 0 | -EUR 6.74M | -EUR 5.65M | n/a | -1 | EUR 2.25M | EUR 1.17M | -EUR 294.00K |
| FY2022 | EUR 0 | -EUR 15.13M | -EUR 12.16M | n/a | -9.59 | EUR 4.63M | EUR 4.09M | -EUR 1.27M |
| FY2021 | EUR 0 | -EUR 14.45M | -EUR 12.40M | n/a | -14.8 | EUR 9.46M | EUR 2.44M | EUR 4.52M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 13.19M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About TME PHARM.CONF.IPO EO 1-
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is mid-stage clinical development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, and glioblastoma.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is TME PHARM.CONF.IPO EO 1-'s market cap?
TME PHARM.CONF.IPO EO 1-'s market capitalization is EUR 13.19M.
What does TME PHARM.CONF.IPO EO 1- do?
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is mid-stage clinical development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, and glioblastoma. It also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy.